Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility. All project work in Thane will be finished at the end of September and Evotec (India) Private Ltd will be wound down from then.
As a consequence 120 people will have to leave the company and Evotec will take a one-time impairment charge of up to EUR 4 m in Q3 2013. At the same time Evotec confirms its revenue, profitability and cash guidance for 2013.
Contact Evotec AG: Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242, werner.lanthaler@evotec.com